Dovitinib (TKI-258, CHIR-258) is a highly potent, orally active small-molecule multi-kinase inhibitor with favorable pharmacokinetic properties, targeting receptors such as FLT3, KIT, and FGFR with IC50 values of 1nM, 2nM, and 8-9nM, respectively[1, 2]. Dovitinib is commonly used in the treatment and research of gastric cancer, pancreatic cancer, advanced breast cancer, multiple myeloma, among others[2, 3].
In vitro, treatment of human liver sinusoidal endothelial SK-HEP1 cells with Dovitinib (1-3μM) for 24h dose-dependently inhibited cell proliferation and induced G2/M cell cycle arrest[4]. Dovitinib (5-15μM) treatment of four hepatocellular carcinoma (HCC) cell lines for 24h induced apoptosis and DNA fragmentation in a dose-dependent manner across all cell lines[5]. Dovitinib (0.001-10μM) treatment of 20 endometrial cancer cell lines for 7 days concentration-dependently inhibited proliferation in all cell lines, but sensitivity varied significantly between them (with up to a 7-fold difference in IC50 values). The FGFR2-mutant MFE280 cell line had the highest sensitivity, with an IC50 value of 0.42μM[6].
In vivo, oral administration of Dovitinib (50 or 75mg/kg/day) to SCID mice bearing 06-0606 patient-derived HCC xenografts for 14 days inhibited tumor growth by 97% and 98%, respectively, without significant body weight loss or other clinical signs of toxicity[4]. Intraperitoneal injection of Dovitinib (30mg/kg; three times weekly) as monotherapy in NOD/SCID mice bearing MKN-45 subcutaneous xenografts for 2 weeks resulted in a net tumor volume reduction to 75% of the original size and a 73% decrease in tumor mass, with no significant change in mouse body weight[7].
References:
[1] TRUDEL S, LI Z H, WEI E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma[J]. Blood, 2005, 105(7): 2941-2948.
[2] ANDRÉ F, BACHELOT T, CAMPONE M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer[J]. Clinical Cancer Research, 2013, 19(13): 3693-3702.
[3] HASINOFF B B, WU X, NITISS J L, et al. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II[J]. Biochemical Pharmacology, 2012, 84(12): 1617-1626.
[4] HUYNH H, CHOW P K, TAI W M, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma[J]. Journal of Hepatology, 2012, 56(3): 595-601.
[5] TAI W T, CHENG A L, SHIAU C W, et al. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1–mediated inhibition of STAT3[J]. Molecular Cancer Therapeutics, 2012, 11(2): 452-463.
[6] KONECNY G E, KOLAROVA T, O'BRIEN N A, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells[J]. Molecular Cancer Therapeutics, 2013, 12(5): 632-642.
[7] CRAWFORD K, BONTRAGER E, SCHWARZ M A, et al. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models[J]. Cancer Biology & Therapy, 2021, 22(10/12): 619-629.
Dovitinib (TKI-258, CHIR-258)是一种高效,具有口服活性和安全药代动力学特性的小分子多激酶抑制剂,作用于FLT3、KIT和FGFR等靶点,IC50值分别为1、2和8-9nM[1,2]。Dovitinib通常用于胃癌、胰腺癌、晚期乳腺癌和多发性骨髓瘤等的治疗和研究[2,3]。
在体外,Dovitinib(1-3μM)处理人肝窦内皮SK-HEP1细胞24h,剂量依赖性地抑制了细胞增殖,并诱导G2/M细胞周期停滞[4]。Dovitinib(5-15μM)处理四种肝细胞癌(HCC)细胞系24h,均以剂量依赖的方式诱导细胞凋亡和DNA碎片化[5]。Dovitinib(0.001-10μM)处理20株子宫内膜癌细胞系7天,能浓度依赖性地抑制所有细胞系的增殖,但各个细胞系间的敏感性差异显著(IC50值差异高达7倍),FGFR2突变细胞系MFE280敏感性最高,IC50值为0.42μM[6]。
在体内,Dovitinib(50或75mg/kg/day)通过口服治疗携带06-0606患者HCC异种移植瘤的SCID小鼠14天,分别抑制了97%和98%的肿瘤生长,且无显著的体重减轻或其它毒性临床体征现象[4]。Dovitinib(30mg/kg; three times weekly)通过腹腔注射单药治疗携带MKN-45皮下异种移植瘤的NOD/SCID小鼠2周,肿瘤净体积缩小为原始的75%,肿瘤质量可减轻73%,且小鼠体重无显著变化[7]。
















